Table 2 Local failure pattern analysis after reirradiation with CIRT vs. VMAT in recurrent head and neck cancer
Pat | ReRT | Failure type | rGTV (ccm) | rGTV Dmean | rGTV D95% | rGTVc Dmean | N failure | M failure | Possible cause of local failure | Salvage treatment |
|---|---|---|---|---|---|---|---|---|---|---|
01 | CIRT | E | 15.9 | 30.4 | 5.7 | 19.4 | No | No | Aberrant areas of recurrence | Best supportive care |
02 | CIRT | E | 4.4 | 6.2 | 1.3 | 2.8 | No | No | Aberrant areas of recurrence | Immunotherapy |
03 | CIRT | A | 1.6 | 63.8 | 62.8 | 63.6 | No | No | Biological/dosimetric failure | Salvage surgery |
04 | VMAT | B and E | 4.6 | 59.1/35.3 | 53.3/10.7 | 60.4/36.2 | No | No | Overgrown recurrence + aberrant areas of recurrence | Immunotherapy |
08 | CIRT | E | 5.4 | 42.1 | 6.9 | 57.9 | Yes | Yes | Improper risk assessment | Salvage surgery |
09 | VMAT | E | 6.6 | 16.5 | 6.2 | 13.4 | No | No | Aberrant areas of recurrence | Chemotherapy |
10 | VMAT | B | 2.2 | 37.4 | 15.0 | 38.9 | Yes | No | Dosimetric failure | Chemotherapy |
14 | CIRT | A and B | 14.8 | 63.8/59.5 | 62.8/45.9 | 63.5/63.0 | No | No | Biological/dosimetric failure + overgrown recurrence | Immunotherapy |
15 | CIRT | B and E | 17.5 | 59.8/0 | 36.3/0 | 63.1/0 | No | No | Overgrown recurrence + aberrant areas of recurrence | Immunotherapy |